Compare Teladoc Health Inc (TDOC) vs Teradyne, Inc. (TER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Teladoc Health Inc vs Teradyne, Inc. — how do they compare? Teladoc Health Inc trades at $5.54 (market cap $1.01B), while Teradyne, Inc. trades at $409.11 (market cap $64.38B). The key difference: Teradyne, Inc. is far larger — about 63.7× Teladoc Health Inc's market cap, and Teradyne, Inc. pays a 0.13% dividend while Teladoc Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Teladoc Health Inc for 39 Days and Teradyne, Inc. for 37 Days on average.
| TDOC | TER | |
|---|---|---|
Market Cap | $1.01B | $64.38B |
Volume | 3,622,440 | 2,394,954 |
Sector | Health | Technology |
52-Week High | $9.72 | $483.84 |
52-Week Low | $4.47 | $132.05 |
Typical Hold Time | 39 Days | 37 Days |
Enterprise Value | $1.27B | $64.12B |
Dividend Yield | — | 0.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Teladoc Health (TDOC) trades at $5.54, down 3.99% in the latest session, reflecting ongoing investor concerns despite recent earnings beats. The stock shows bearish technical signals with oversold conditions while fundamentals reveal a mixed picture - strong gross margins of 68.97% but persistent net losses. Recent management changes and legal investigations add uncertainty, though the company maintains solid cash flow from operations of $294.36 million.
TDOC presents a high-risk opportunity with significant upside potential given the $8.83 consensus price target, representing 59% upside. However, continued net losses, negative cash flow trends, and competitive pressures in telehealth create substantial execution risk. The stock's current valuation at 0.4x sales appears attractive if the company can achieve profitability.
Teradyne (TER) trades at $398.72, down 7.34% over 24 hours, but maintains strong technical support near $399. The company demonstrates robust fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and expanding AI-driven test portfolio through new products like Magnum E2 and Iris 100. Revenue growth is projected to accelerate from $3.19B in 2025 to $4.5B in 2026, with net income margin improving to 25.76%.
Outlook remains positive with 61% analyst buy ratings and $461.50 consensus price target, representing 16% upside. Key risks include semiconductor cycle volatility and competitive pressure from KLAC & COHU. Institutional accumulation continues with recent purchases by Envestnet and Nykredit, supporting bullish sentiment despite insider selling.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
